KineMed enters two-year AD collaboration with Bristol-Myers Squibb
USA-based KineMed, a translational and personalized medicine development company, has entered a two-year collaboration with Bristol-Myers Squibb for the development of new candidates for the treatment of Alzheimer's disease and other neurodegenerative conditions. The collaboration will apply KineMed's stable isotope technology to identify novel biomarkers that can be used to assess the extent and treatment of AD. "KineMed has a unique approach to identifying biomarkers for neurodegenerative diseases," said Francis Cuss, senior vice president of Discovery and Exploratory Clinical Research at B-MS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze